Supernus Pharmaceuticals on Pace for Longest Winning Streak Since July 2024 -- Data Talk

Dow Jones2025-12-20

Supernus Pharmaceuticals, Inc. (SUPN) is currently at $51.78, up $2.50 or 5.07%

 

--Would be highest close since Nov. 4, 2025, when it closed at $57.00

--On pace for largest percent increase since Aug. 6, 2025, when it rose 13.08%

--Currently up 12 of the past 13 days

--Currently up eight consecutive days; up 14% over this period

--Longest winning streak since July 19, 2024, when it rose for 12 straight trading days

--Best eight-day stretch since the eight days ending Aug. 13, 2025, when it rose 20.1%

--Up 9.80% this week; best weekly performance since the week ending Aug. 8, 2025, when it rose 16.12%

--Up 13.58% month-to-date

--Up 43.2% year-to-date; on pace for best year since 2017, when it rose 57.82%

--Down 13.48% from its all-time closing high of $59.85 on June 29, 2018

--Up 46.15% from 52 weeks ago (Dec. 20, 2024), when it closed at $35.43

--Down 9.16% from its 52-week closing high of $57.00 on Nov. 4, 2025

--Up 70.95% from its 52-week closing low of $30.29 on April 21, 2025

--Traded as high as $52.11; highest intraday level since Nov. 4, 2025, when it hit $57.40

--Up 5.74% at today's intraday high; largest intraday percent increase since Oct. 9, 2025, when it rose as much as 7.87%

 

All data as of 2:48:01 PM ET

 

Source: Dow Jones Market Data, FactSet

 

(END) Dow Jones Newswires

December 19, 2025 14:52 ET (19:52 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment